Last updated on November 2017

A PHASE II MULTI-CENTER, RANDOMIZED, DOUBLEBLIND, 24-WEEK, 3-ARM, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO5285119 IN CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER (ASD)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Autism
  • Age: Between 5 - 17 Years
  • Gender: Male or Female
  • Other:

    Eligibility Criteria:


    Parent or legal guardian/representative and caregiver willing and able to give written informed consent according to local requirements and subject willing and able to provide informed assent or consent according to local requirements


Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.